Lung Cancer

NHCPRC Guidelines

National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version)
National Health Commission of the People’s Republic of China

Original Article

IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer
Yi-Long Wu,Shun Lu,Gongyan Chen,Jianxing He,Jifeng Feng,Yiping Zhang,Liyan Jiang,Hongming Pan,Jianhua Chang,Jian Fang,Amy Cai,Lilian Bu,Jane Shi,Jinjing Xia
Lung cancer burden and trends from 2000 to 2018 in China: Comparison between China and the United States
Yi Teng,Changfa Xia,Maomao Cao,Fan Yang,Xinxin Yan,Siyi He,Mengdi Cao,Shaoli Zhang,Qianru Li,Nuopei Tan,Jiachen Wang,Wanqing Chen
A novel multimodal prediction model based on DNA methylation biomarkers and low-dose computed tomography images for identifying early-stage lung cancer
Jing Zhang,Haohua Yao,Chunliu Lai,Xue Sun,Xiujuan Yang,Shurong Li,Yubiao Guo,Junhang Luo,Zhihua Wen,Kejing Tang
Genetic susceptibility loci of lung cancer are associated with malignant risk of pulmonary nodules and improve malignancy diagnosis based on CEA levels
Zhi Li,Liming Lu,Yibin Deng,Amei Zhuo,Fengling Hu,Wanwen Sun,Guitian Huang,Linyuan Liu,Boqi Rao,Jiachun Lu,Lei Yang
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer: A real-world, multicenter, retrospective, controlled study in China
Hanxiao Chen,Xiangjuan Ma,Jie Liu,Yu Yang,Yong Fang,Liping Wang,Jian Fang,Jun Zhao,Minglei Zhuo
Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update
Jun Lu,Tianqing Chu,Hongyu Liu,Minjuan Hu,Yuqing Lou,Yanwei Zhang,Zhiqiang Gao,Wei Zhang,Xueyan Zhang,Huimin Wang,Hua Zhong,Baohui Han